Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02663518 · ClinicalTrials.gov registry record · Phase 1
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 249
- Enrollment target
NCT02663518 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 249 participants.
The verdict
NCT02663518, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 249 participants
- Enrollment target
Study Summary
Multicenter, open-label, phase 1a/1b trial of PF-07901800 (TTI-621) in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
Interventions
- DRUG PF-0791800 (TTI-621)
- DRUG PF-07901800 (TTI-621) plus Rituximab
- DRUG PF-07901800 (TTI-621) plus Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 249 participants |
| Start Date | 2016-01-28 |
| Est. Completion | 2022-11-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02663518
The ClinicalTrials.gov registry entry for NCT02663518 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 249 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PF-0791800 (TTI-621) is the first listed.
NCT02663518 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02663518 about?
NCT02663518 is a clinical study titled "A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors". Multicenter, open-label, phase 1a/1b trial of PF-07901800 (TTI-621) in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
What is the current status of trial NCT02663518?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 249 participants. The study started on 2016-01-28. Estimated completion is 2022-11-23.
What interventions are being tested in trial NCT02663518?
The interventions under investigation include: PF-0791800 (TTI-621) (DRUG), PF-07901800 (TTI-621) plus Rituximab (DRUG), PF-07901800 (TTI-621) plus Nivolumab (DRUG).
Who is sponsoring clinical trial NCT02663518?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.